Algert Global’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$87.8K Buy
+13,820
New +$95.8K ﹤0.01% 1282
2026
Q1
– Sell
-128,611
Closed -$1.32M – 1333
2025
Q4
$1.32M Sell
128,611
-1,201
-0.9% -$10.1K 0.02% 794
2025
Q3
$753K Buy
+129,812
New +$759K 0.01% 877

Other funds holding TRDA

Algert Global's TRDA Position: Q3 2026 in Review

Algert Global opened a new position in Entrada Therapeutics (TRDA) in Q3 2026: 13,820 shares worth $87.8K. The stake represents ﹤0.01% of the portfolio and ranks #1282 among its holdings. This is a return to the name: Algert Global previously reported a position in TRDA as recently as Q4 2025.

Algert Global first reported a position in TRDA in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.32M in Q4 2025. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Algert Global held 13,820 shares of Entrada Therapeutics worth $87.8K as of Q3 2026.
  • Entrada Therapeutics was a new Algert Global position in Q3 2026.
  • Entrada Therapeutics made up ﹤0.01% of Algert Global's portfolio in Q3 2026, its #1282 holding.
  • Algert Global first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Algert Global's Entrada Therapeutics position peaked at $1.32M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Algert Global's 13F filing for Q3 2026, filed 17 Nov 2026.